Artivion (AORT) reported $441M in revenue for fiscal 2025, +13.6% year on year. That ranks #2297 by revenue among 2853 SEC filers and #224 in Healthcare. Net income was $9.8M, a net margin of 2.2%. Revenue has grown 9.8% a year on average since 2011 ($120M then). The fiscal 2025 balance sheet shows $885M in total assets, $64.9M in cash and $215M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $441M | +13.6% | FY20252025-12-31 |
| Gross profitGrossProfit | $284M | +14.2% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $33.7M | −13.2% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $9.8M | +$23.1M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $39.9M | +79.3% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $39.0M | +249.0% | FY20252025-12-31 |
| Total assetsAssets | $885M | +12.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $448M | +62.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $64.9M | +21.4% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $215M | −31.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $116M | $1.4M | Open → |
| Q2 20262026-06-30 | $126M | −$13.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Artivion, Inc.
- Ticker
- AORT
- Exchange
- NYSE
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0000784199
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 18, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Zai LabZLAB | $460M | −$176M |
| AccurayARAY | $459M | −$1.6M |
| Tarsus PharmaceuticalsTARS | $451M | −$66.0M |
| ArtivionAORT | $441M | $9.8M |
| Genedx HoldingsWGS | $428M | −$21.0M |
| Mimedx GroupMDXG | $419M | $48.6M |
| InnovivaINVA | $411M | $271M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Artivion — Key figures |url=https://companiesranked.com/en/company/artivion |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Artivion — Key figures. CompaniesRanked. https://companiesranked.com/en/company/artivionBibTeX
@misc{companiesranked-en-company-artivion-2026,
author = {{CompaniesRanked}},
title = {{Artivion — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/artivion}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-009046 · February 18, 2026
{{cite web |title=Artivion — Key figures — 10-K (0001628280-26-009046) |url=https://www.sec.gov/Archives/edgar/data/784199/000162828026009046/aort-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-18}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.